ABCB5 as a Prognostic Marker in Survival of Cultivated Limbal Stem Cell Transplantation
ABCB5 as a Prognostic Marker in Survival of Cultivated Limbal Stem Cell Transplantation Expanded in Vitro on Amniotic Membrane in Patients With Limbal Stem Cell Deficiency.
Sponsor: Instituto de Oftalmología Fundación Conde de Valenciana
Terminated
Preliminar results not favorable
Listed as NCT02579993, this NA trial focuses on Limbal Stem Cell Deficiency and remains terminated or withdrawn. Sponsored by Instituto de Oftalmología Fundación Conde de Valenciana, it has been updated 6 times since 2015, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Terminated NA
-
Jul 2024 — Sep 2024 [monthly]
Terminated NA
-
Jan 2021 — Jul 2024 [monthly]
Terminated NA
-
Jun 2018 — Jan 2021 [monthly]
Terminated NA
-
Mar 2018 — Jun 2018 [monthly]
Terminated NA
Status: Recruiting → Terminated
▶ Show 1 earlier version
-
Jan 2017 — Mar 2018 [monthly]
Recruiting NA
First recorded
Mar 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Instituto de Oftalmología Fundación Conde de Valenciana
- National Council of Science and Technology, Mexico
For direct contact, visit the study record on ClinicalTrials.gov .